Comparing the current results to its competitors, Indivior Pharmaceuticals Inc reported Revenue increase in the 1 quarter 2026 by 19.62 % year on year. The sales growth was above Indivior Pharmaceuticals Inc 's competitors' average revenue growth of 11.42 %, achieved in the same quarter.
Indivior Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company faces challenges in obtaining regulatory authorization, delays in clinical trials, and issues related to patent validity and enforceability. There are risks of patent interference or derivation proceedings, as well as potential costs associated with patent litigation. The company relies on trade secrets and confidentiality agreements to protect its competitive position but recognizes the risk of independent development by others. Competitors may possess greater resources to support intellectual property litigation. Market factors such as competitors' strategic actions, the introduction of new competing products, and regulatory changes can contribute to stock price volatility and affect investor returns.
Overall company sales advanced by 19.62 % Indivior Pharmaceuticals Inc outperformed its competitors in this segment and improved market share, to approx. 7.04 %. << More on INDV Market Share.
*Market share is calculated based on total revenue.
Publicly Traded Peers of Indivior Pharmaceuticals Inc
Alzamend Neuro Inc Share Performance
+2.10%
Over The Past 5 Days
Alzamend Neuro Inc
Profile
Alzamend Neuro Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for Alzheimer's disease and other neurological disorders. Their business model revolves around conducting extensive research and clinical trials to develop groundbreaking treatments that address the underlying causes of these debilitating conditions. With a focus on creating value for patients, healthcare providers, and shareholders, they aim to bring effective therapies to market and improve the quality of life for those affected by neurodegenerative diseases.
Amneal Pharmaceuticals Inc operates as a fully integrated pharmaceutical company, primarily focused on the development, manufacturing, and distribution of generic and specialty pharmaceutical products. Their business model revolves around identifying market opportunities, conducting research to develop cost-effective formulations, and leveraging their expansive manufacturing capabilities to produce and distribute a wide range of pharmaceuticals to customers globally. Additionally, they aim to provide high-quality products at competitive prices while continuously investing in research and development to expand their product portfolio.
Anebulo Pharmaceuticals Inc operates on a business model focused on developing and commercializing innovative therapeutic solutions for respiratory diseases. They aim to identify and target unmet medical needs through research and development of novel drug formulations and delivery systems. By partnering with stakeholders and leveraging their expertise, Anebulo Pharmaceuticals Inc aims to provide effective treatments and improve the lives of patients with respiratory conditions.
Aquestive Therapeutics Inc follows a business model that focuses on the development and commercialization of innovative products to address unmet medical needs. The company primarily operates in the pharmaceutical industry, leveraging its proprietary drug delivery technology to create and improve various medications for patients.
Assertio Holdings Inc is a pharmaceutical company that operates through its subsidiary, Assertio Therapeutics Inc. The company focuses on developing and commercializing pain and other related products, primarily for the management of chronic diseases. Assertio's business model revolves around research, development, and marketing of innovative medications to improve patient outcomes and quality of life.
Sources:
Indivior Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Indivior Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
